A Phase III, Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Assess the Efficacy and Safety of Tocilizumab in Subjects With Giant Cell Arteritis

Trial Profile

A Phase III, Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Assess the Efficacy and Safety of Tocilizumab in Subjects With Giant Cell Arteritis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Dec 2017

At a glance

  • Drugs Tocilizumab (Primary) ; Methotrexate; Prednisone
  • Indications Giant cell arteritis
  • Focus Registrational; Therapeutic Use
  • Acronyms GiACTA
  • Sponsors Roche
  • Most Recent Events

    • 19 Dec 2017 Results published in the Annals of Internal Medicine
    • 08 Nov 2017 Results of post hoc exploratory analysis assessing patient reported outcomes in patients treated with QW tocilizumab for 52 weeks presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
    • 08 Nov 2017 Results comparing GiACTA trial data from those of a national multicenter series of patients with GCA from the clinical practice, focusing on the baseline characteristics of the patients, were presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top